Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

There is an unmet need for repigmentation therapies for patients with nonsegmental vitiligo (NSV) who are candidates for systemic therapy.

By Ezzedine, Lui, Eleftheriadou +15Nature medicineNov 2, 2026

Score█████░░░░░5.2

Key numbers

75% improvement in the facial
18.9% versus 6.8%
95% confidence interval 1.6-5.9

VerdictA leading story on any desk.

Read the original

Abstract

There is an unmet need for repigmentation therapies for patients with nonsegmental vitiligo (NSV) who are candidates for systemic therapy. Here, 52-week primary results are reported from two parallel phase 3, randomized, double-blind, placebo-controlled trials of once-daily povorcitinib (oral, highly selective JAK1 inhibitor) 30 mg in adults with moderate-to-severe NSV (STOP-V1 and STOP-V2). STOP-V1 and STOP-V2 enrolled 467 and 449 patients, respectively. In both studies, the primary endpoint of ≥75% improvement in the facial Vitiligo Area Scoring Index (F-VASI75) at week 52 was met, demonstrating statistically significant and clinically meaningful repigmentation with povorcitinib versus placebo (STOP-V1: 18.9% versus 6.8%; odds ratio, 3.1; 95% confidence interval 1.6-5.9; P = 0.0003; STOP-V2: 18.9% versus 3.1%; odds ratio, 7.5; 95% confidence interval 3.0-18.6; P < 0.0001). Povorcitinib was well tolerated; the percentage of patients with any treatment-emergent adverse event (TEAE) was similar between the povorcitinib and placebo groups in both studies (STOP-V1/STOP-V2, 68.7%/66.7% versus 63.7%/62.7%). The most common TEAEs with povorcitinib were nasopharyngitis (STOP-V1/STOP-V2, 11.2%/11.3% versus placebo, 9.8%/11.1%), acne (10.7%/10.8% versus 3.0%/2.2%) and upper respiratory tract infection (6.9%/14.0% versus 9.0%/10.7%). Serious TEAEs were generally single events, and Janus kinase inhibitor class-specific TEAEs were absent or rare. These results support once-daily povorcitinib as an effective and well-tolerated systemic treatment for adults with moderate-to-severe NSV. ClinicalTrials.gov identifiers: NCT06113445, NCT06113471 .

Khaled Ezzedine, Harvey Lui, Viktoria Eleftheriadou, Seemal R Desai, Thierry Passeron, Julien Ringuet, Nanja van Geel, Albert Wolkerstorfer, Charles Lynde, Matthias Augustin, José Luis López-Estebaranz, Pearl Grimes, David Rosmarin, Kurt Brown, Shaoceng Wei, Sunanda Karanam, Deanna Kornacki, Amit G Pandya

The editor's rubric

Heuristic review

Leverage2 / 5: Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).; 10% of this desk’s rubric
Magnitude3 / 5: Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.; 20% of this desk’s rubric
Evidence5 / 5: Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.; 32% of this desk’s rubric
Novelty2 / 5: A new combination of known ideas.; 8% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 5% of this desk’s rubric
Stakes3 / 5: Meaningful benefit to many people within a few years.; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	██░░░2/5	10%	Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
Magnitude	███░░3/5	20%	Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
Evidence	█████5/5	32%	Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.
Novelty	██░░░2/5	8%	A new combination of known ideas.
Trajectory	██░░░2/5	5%	Some room to improve with obvious engineering.
Stakes	███░░3/5	25%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: gains (versus baseline, efficacy); design (randomized, blinded, placebo-controlled); verification (confidence interval, p-value); scale (improves with scale); stakes (major disease, prevention or cure).

How the score was computed

rank-2026-10-18

Score█████░░░░░5.2

Score = 10 × (80% × adjusted merit / 10 + 10% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 6.8 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 5.4 / 10; Shrunk toward the desk prior by editor confidence (50%).
Attention: 0%; Citations, upvotes, points, mentions.
Freshness: 85%; Half-life decay since publication.

Citations0 (reference 20, via openalex, Nov 4, 2026, 06:17 UTC)

The record

Reviewed by heuristic-v10 on Nov 4, 2026, 06:17 UTC. Paper type: clinical.
Categories: Journal Article
TOP, No.2 in the Front page edition of November 4, 2026.
TOP, No.4 in the Medicine edition of November 4, 2026.